These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21591319)

  • 21. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
    Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J; Holmes MV; Preiss D
    J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia.
    Tall A; Sammett D; Granot E
    J Clin Invest; 1986 Apr; 77(4):1163-72. PubMed ID: 3958185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
    de Vries R; Borggreve SE; Dullaart RP
    Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
    Okamoto H; Miyai A; Sasase T; Furukawa N; Matsushita M; Nakano T; Nakajima K
    Clin Chim Acta; 2007 Jan; 375(1-2):92-8. PubMed ID: 16859664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Curr Opin Lipidol; 2006 Aug; 17(4):394-8. PubMed ID: 16832162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
    Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
    Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure.
    Martinelli AEM; Maranhão RC; Carvalho PO; Freitas FR; Silva BMO; Curiati MNC; Kalil Filho R; Pereira-Barretto AC
    Lipids Health Dis; 2018 Oct; 17(1):242. PubMed ID: 30342531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
    Briand F; Thieblemont Q; André A; Ouguerram K; Sulpice T
    Clin Transl Sci; 2011 Dec; 4(6):414-20. PubMed ID: 22212222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
    Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
    Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.